skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
HDAC Inhibitor CHR-3996 (Code C78475)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: HDAC Inhibitor CHR-3996

Definition: An orally bioavailable, second-generation hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor CHR-3996 inhibits HDAC, resulting in an accumulation of highly acetylated histones, the induction of chromatin remodeling, and the selective transcription of tumor suppressor genes; these events may result in the inhibition of tumor cell division and the induction of tumor cell apoptosis. This agent may upregulate HSP70 and downregulate anti-apoptotic Bcl-2 proteins more substantially than some first-generation HDAC inhibitors. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins.

Label: HDAC Inhibitor CHR-3996

NCI Thesaurus Code: C78475 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2703120  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
HDAC Inhibitor CHR-3996
Histone Deacetylase Inhibitor CHR-3996

External Source Codes: 
PDQ Closed Trial Search ID 600512
PDQ Open Trial Search ID 600512 (check for NCI PDQ open clinical trial info)
UMLS CUI C2703120

Other Properties:
     Name Value (qualifiers indented underneath)
code C78475
Legacy_Concept_Name HDAC_Inhibitor_CHR-3996
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom